Optimal Reperfusion Strategy for STEMI Patients With Anticipated PPCI Delay

Inclusion Criteria: * Aged 18 or over and less than 75 years old; * Patents with STEMI with symptom onset persisted more than 30mim and within 6 h before randomization; * ECG \>=2 mm ST-segment elevation in 2 contiguous precordial leads or \>=1 mm ST- segment elevation in 2 contiguous extremity leads, or new left bundle branch block; * Patents with an expected time from FMC to PCI \>=120 min. * Signed informed consent form prior to trial participation. Exclusion Criteria: * Fibrinolysis contradictions: Definite hemorrhagic stroke history;ischemic stroke or cerebrovascular accident in nearly 6 months; * Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) or recent trauma to the head or cranium (i.e. \< 3 months); * Active bleeding or known bleeding disorder/diathesis; Recent administration of any i.v. or s.c. anticoagulation within 12 hours including unfractionated heparin, enoxaparin and/or bivalirudin or current use of oral anticoagulation (warfarin or coumadin); * Arterial aneurysm, arterial/venous malformation and aorta dissection; Uncontrolled hypertension, defined as a single blood pressure measurement \>=180/110 mm Hg (systolic BP \>=180 mm Hg and/or diastolic BP \>=110 mm Hg) prior to randomisation; * Major surgery, biopsy of a parenchymal organ, noncompressible vascular puncture, or significant trauma within the past 2 months (this includes any trauma associated with the current myocardial infarction); * prolonged or traumatic cardiopulmonary resuscitation (\> 10 minutes) within the past 2 weeks; major surgery pending in the following 30 days. 2. Complex heart condition Evidence of cardiac rupture; Pre-existing heart failure and previous New York heart function classification III-IVCardiogenic shock (SBP \<90mmHg after fluid infusion or SBP\<100mmHg after vasoactive drugs); * PCI within previous 1 month or previous bypass surgery; * Myocardial infarction in the past year or previously known coronary artery disease not suitable for revascularization; * Known acute pericarditis and/or subacute bacterial endocarditis; * Hospitalization for cardiac reason within past 48 hours; * Severe comorbidity: Other diseases with life expectancy \<=12 months; * Any history of severe renal or hepatic dysfunction (hepatic failure, cirrhosis, portal hypertension or active hepatitis); * neutropenia, thrombocytopenia; * Severe COPD with hypoxemia; * Not suitable for clinical trial: Inclusion in another clinical trial; Previous enrollment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days; * Pregnant or lactating; * Body weight \<40kg; * Known hypersensitivity to any drug that may be used in the study; * Inability to follow the protocol and comply with follow-up requirements or any other reason the investigator feels would place the patient at increased risk.